spacer
MAGAZINE EBOOKS
View digital versions
of our magazines
exactly as they
appear in print





International Clinical Trials
International Clinical Trials
ICT is a specialist journal designed to provide global coverage of key topics pertinent to the clinical trials sector.
 
European Pharmaceutical Contractor
European Pharmaceutical Contractor
The EPC edition is designed to fill a unique position in pharmaceutical contractor publishing.
 
European Biopharmaceutical Review
European Biopharmaceutical Review
EBR is well-recognised for providing beneficial information to players in the bio-industry including entrepreneurial biopharmaceutical and life science companies
 
Pharmaceutical Manufacturing and Packing Sourcer
Pharmaceutical Manufacturing and Packing Sourcer
PMPS is a specialist journal designed to provide worldwide coverage of a range of topics relating to the pharmaceutical manufacturing and packaging sector.
 
Innovations in Pharmaceutical Technology
Innovations in Pharmaceutical Technology
IPT was launched in 1997 to provide the pharmaceutical industry with quality information on the latest cutting-edge technologies.
 
Features
Social Media in Orphan Disease Research

The New Imperative

Barbara Zupancic at Worldwide Clinical Trials evaluates the revolution of social media in clinical research and its newfound importance to the recruitment of rare and orphan disease subjects.
 
Good Clinical Practice
Expert Guidance on Inspection Processes

Dispelling the Fears of Inspection

NIHR’s Ross Downes guides you through the daunting process of GCP and MHRA inspections, from documentation and recruitment strategy to the importance of obtaining consent.
 
In Brief
In Brief

Vax Populi

EBR’s Industry Advisor, Emile Bellott, discusses the health achievement of vaccinations against infectious diseases in the post-industrial era, and how immunisation is essential to continue saving millions of lives every year.

 
Cold Chain Challenges
Pharma Cold Chain

The Impact of Emerging Trends

Dr Ruediger Lomb at World Courier examines the pharmaceutical cold chain, noting the trend towards more high-precision, low-volume therapies, but also the negative trend of growing prices.

 

 

Website design and development by Rubler Studio
spacer

Member login

E-mail address:

Password:
Remember me

.
News and Press Releases

Innovative Micro-Infusion Pump for Gerresheimer Subsidiary Sensile Medical Developed and Successfully Launched for EVER Pharma

Düsseldorf/Olten, July 03, 2019 – Developed specially by Sensile Medical for EVER Pharma under the brand name D-mine®, this wearable microinfusion pump recently received European CE certification and has already been launched in several European countries. The compact, patient-friendly infusion pump is used for the continuous subcutaneous administration of drugs to treat Parkinson’s disease. The first micro pump from Gerresheimer subsidiary Sensile Medical to be available on the market, it gives Parkinson’s patients greater independence in their day-today lives.
More info >>

.
White Papers

Is Your Biobank Ready for the Challenge of Biomarker-based Research?

BioFortis

Targeted and personalized studies with well-defined patient segmentation biomarkers are becoming the norm in clinical trials. This increased interest in molecular biomarker studies necessitates a rigor and sophistication in sample management within the clinical trial context that is often not supported either by traditional clinical trial management software (CTMS), or biobanking systems.  Download our Next Generation Biobanking whitepaper and learn about how to overcome the key challenges in clinical trial sample management from working in a distributed network of partners and stakeholder to managing consents and generating scientific insights.
More info >>



Industry Events

ESMO Targeted Anticancer Therapies Congress 2020

2-4 March 2020, Paris, France

A unique and international mix of experts, researchers and decision makers both from academia and industry across the globe, will convene in Paris for a three-day Congress aiming at exchanging knowledge, experience and research innovations in cancer. TAT 2020 will focus, among others, on novel strategies in immuno-oncology, personalised medicine and molecular tumour boards, preclinical studies to identify effective combination therapies, use of microbiome, tumour agnostic trials, ADC technology, oncolytics, multispecific biological constructs and targeting cytokines. Participating in TAT 2020 will offer you the possibility to take part in interdisciplinary discussions inspiring new ideas and new collaborations.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement